ONCOS-102 is one of the most promising oncolytic viruses with >200 patients treated. Targovax stock has been under pressure for years after equity offerings at fairly low pricing, but has been making a strong move recently, quite without many investors taking notice. Norwegian Biotech especially in the field of cancer immunotherapy may be ready for a new round of...
As you know from my last analysis, TRVX gave a buy signal on the weekly chart last friday. Now looking more closely for a good entry. There is a smal gap down to 7.27, which I can easily see filled with a retest of the recently broken black trendline. 2 things will be providing support now, the horizontal support around NOK 6.75-7.20 and the blue upward trendline....
Fundamental analysts give Targovax a big BUY, with a target of around NOK 19,-. I've been waiting for a clear signal of support lately and it has just been formed. IF the weekly candle closes more or less the way it is now, several positive buy signals are there: - Long term blue downward trendline got broken and retested. Clear support found on retest. -...
Analysts, from a fundamental point of view, are giving TRVX huge potential with a target of around 19. Reason enough to look at the chart. So TRVX still seems to find support around 7.00-7.40. I'm looking for a reaction upwards at the top of the daily cloud and thus breaking out of the descending triangle that has been forming. This can happen any time now! If...
TRVX needs to hold this current support AND get back into the 4h cloud for it to become a buy. I'll looking at it once it can break the black downward short term trendline.
Targovax OSL:TRVX a clinical phase norwegian Biotech is currently at market cap NOK 327 million / 35 million USD. Value inflection point very close as the company will need to raise funds in the very near future, which must either come from investors or from a possible partner deal. PRESENTATION OF ONCOS-102 MELANOMA DATA AT SITC ANNUAL MEETING ...